227 related articles for article (PubMed ID: 17615761)
1. [3 questions about gastrointestinal risk. Are coxibs here clearly better than NSAID?]].
Krüger K
MMW Fortschr Med; 2006 Nov; 148(48):12. PubMed ID: 17615761
[No Abstract] [Full Text] [Related]
2. [Coronary risks with NSAID and coxibs. The end of hysteria].
Einecke D
MMW Fortschr Med; 2006 Nov; 148(48):10, 12. PubMed ID: 17615760
[No Abstract] [Full Text] [Related]
3. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Cannon CP; Curtis SP; FitzGerald GA; Krum H; Kaur A; Bolognese JA; Reicin AS; Bombardier C; Weinblatt ME; van der Heijde D; Erdmann E; Laine L;
Lancet; 2006 Nov; 368(9549):1771-81. PubMed ID: 17113426
[TBL] [Abstract][Full Text] [Related]
4. [By what means does the rheumatic patient with gastrointestinal risks fare best?].
Einecke D
MMW Fortschr Med; 2007 Mar; 149(10):18. PubMed ID: 17408040
[No Abstract] [Full Text] [Related]
5. The ever growing story of cyclo-oxygenase inhibition.
Rodríguez LA; Patrignani P
Lancet; 2006 Nov; 368(9549):1745-7. PubMed ID: 17113403
[No Abstract] [Full Text] [Related]
6. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis.
Feng X; Tian M; Zhang W; Mei H
PLoS One; 2018; 13(1):e0190798. PubMed ID: 29320568
[TBL] [Abstract][Full Text] [Related]
7. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Laine L; Curtis SP; Cryer B; Kaur A; Cannon CP;
Lancet; 2007 Feb; 369(9560):465-73. PubMed ID: 17292766
[TBL] [Abstract][Full Text] [Related]
8. [Comparative evaluation of the safety and efficacy of etoricoxib and diclofenac on the upper gastrointestinal tract in patients with osteoarthrosis and rheumatoid arthritis (the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study program)].
Alekseeva LI
Ter Arkh; 2010; 82(8):57-62. PubMed ID: 20873248
[TBL] [Abstract][Full Text] [Related]
9. [NSAID therapy. Gastrointestinal risks of classic NSAID are underestimated].
MMW Fortschr Med; 2010 May; 152(20):46-7. PubMed ID: 20552882
[No Abstract] [Full Text] [Related]
10. Clinical use and pharmacological properties of selective COX-2 inhibitors.
Shi S; Klotz U
Eur J Clin Pharmacol; 2008 Mar; 64(3):233-52. PubMed ID: 17999057
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of the newest COX-2 selective inhibitors in rheumatic disease.
Baraf HS
Curr Pharm Des; 2007; 13(22):2228-36. PubMed ID: 17691996
[TBL] [Abstract][Full Text] [Related]
12. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
[TBL] [Abstract][Full Text] [Related]
13. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
Cannon CP; Curtis SP; Bolognese JA; Laine L;
Am Heart J; 2006 Aug; 152(2):237-45. PubMed ID: 16875903
[TBL] [Abstract][Full Text] [Related]
14. [Non-selective NSAIDs and coxibs: what are myths, what are facts?].
MMW Fortschr Med; 2013 Jun; 155(12):56-7. PubMed ID: 23923320
[No Abstract] [Full Text] [Related]
15. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
Chan FK; Lanas A; Scheiman J; Berger MF; Nguyen H; Goldstein JL
Lancet; 2010 Jul; 376(9736):173-9. PubMed ID: 20638563
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
Krueger K; Lino L; Dore R; Radominski S; Zhang Y; Kaur A; Simpson R; Curtis S
Ann Rheum Dis; 2008 Mar; 67(3):315-22. PubMed ID: 17965424
[TBL] [Abstract][Full Text] [Related]
17. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs.
Ray WA; Chung CP; Stein CM; Smalley WE; Hall K; Arbogast PG; Griffin MR
Gastroenterology; 2007 Sep; 133(3):790-8. PubMed ID: 17854591
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal safety of NSAIDs versus COX-2 inhibitors.
Parashar A
Lancet; 2007 Apr; 369(9570):1343-1344. PubMed ID: 17448812
[No Abstract] [Full Text] [Related]
19. NSAID trials and the choice of comparators--questions of public health importance.
Psaty BM; Weiss NS
N Engl J Med; 2007 Jan; 356(4):328-30. PubMed ID: 17251528
[No Abstract] [Full Text] [Related]
20. [Selective cox-2 inhibitors. Better tolerance than NSAID plus antacid].
MMW Fortschr Med; 2004 Apr; 146(15):66. PubMed ID: 15373027
[No Abstract] [Full Text] [Related]
[Next] [New Search]
